260441-48-3

Upstream product

• 95-77-2 3,4-dichlorophenol 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 1972-28-7 diethylazodicarboxylate 

Downstream Products

• 485391-81-9 C₂₃H₂₇Cl₂N₃O₄S 
• 1413286-13-1 C₂₅H₂₆Cl₂N₄O₄ 
• 1413286-12-0 C₂₄H₂₆Cl₂N₂O₄ 
• 1413286-11-9 C₂₄H₂₆Cl₂N₂O₄ 
• 367497-18-5 C₂₅H₂₈Cl₂N₂O₅ 
• 367500-72-9 4-(3,4-Dichloro-phenoxy)-[1,4']bipiperidinyl-1'-carboxylic acid tert-butyl ester 
• 367500-74-1 4-(3,4-dichloro-phenoxy)-[1,4']bipiperidine 
• 1413286-17-5 C₂₉H₃₄Cl₂N₆O₄ 
• 1413286-16-4 C₂₆H₃₁Cl₂N₃O₄ 
• 1413286-15-3 C₂₇H₃₂Cl₂N₂O₆S 
• 1413286-14-2 C₂₄H₂₆Cl₂N₆O₂ 
• 245057-73-2 4-(3,4-dichloro-phenoxy)-piperidine 

Relevant academic research and scientific papers

The discovery of CCR3/H1 dual antagonists with reduced hERG risk

A series of dual CCR3/H1 antagonists based on a bispiperidine scaffold were discovered. Introduction of an acidic group overcame hERG liability. Bioavailability was optimised by modulation of physico-chemical properties and physical form to del

Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP)

Arylpiperazines of formula (I) useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13.

Chemical compounds

The invention provides compounds of formula (I): as modulators of chemokine and H1 receptor activity. The compounds are especially useful in the treatment of asthma and rhinitis.

NOVEL AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS

This invention relates to novel aza-dng dedvatives useful as monoamine neurotransmifter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

Chemical compounds

The invention concerns compounds of formula (I), and their use in therapy, particularly in the modulation of CCR3 activity.

Chemical compounds

The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.